Allogeneic bone marrow transplantation in patients with lymphoma relapsing after autologous marrow transplantation.

abstract：:Graft failure is a major concern after cord blood transplantation (CBT) or HLA-haploidentical transplantation (haplo-SCT). As patients who undergo CBT or haplo-SCT almost always lack both matched-related and -unrelated donors, salvage transplantation would also be limited to either CBT or haplo-SCT. In this study, we ...

journal_title：Bone marrow transplantation

authors： Yoshihara S,Ikegame K,Taniguchi K,Kaida K,Kim EH,Nakata J,Kato R,Inoue T,Fujioka T,Tamaki H,Okada M,Soma T,Ogawa H

更新日期：2012-03-01 00:00:00

abstract：:The severe phenotype of leukocyte adhesion deficiency is a rare, congenital disorder of leukocyte function that is usually fatal in the first few years of life. Allogeneic hematopoietic stem cell transplantation currently offers the only curative approach for this disease. We describe the first successful matched unre...

journal_title：Bone marrow transplantation

authors： Mancias C,Infante AJ,Kamani NR

更新日期：1999-12-01 00:00:00

abstract：:In comparison to bone marrow, umbilical cord blood has decreased intrinsic immune responsiveness allowing transplantation across HLA barriers with lower rates of graft-versus-host disease. However, laboratory models have also suggested that cord blood may be extremely sensitive to stimulation by cytokines. We report a...

journal_title：Bone marrow transplantation

authors： Goldberg SL,Pecora AL,Rosenbluth RJ,Jennis AA,Preti RA

更新日期：2000-08-01 00:00:00

abstract：:Current graft-versus-host disease (GVHD) prophylaxis is not uniformly successful. Since the development of GVHD has a profound impact on transplant success, treatment is required. The mainstay of therapy has been glucocorticoids (steroids), along with anti-thymocyte globulin, cyclosporine, monoclonal antibodies, and a...

journal_title：Bone marrow transplantation

authors： Deeg HJ,Henslee-Downey PJ

更新日期：1990-07-01 00:00:00

abstract：:In an attempt to improve the dismal prognosis of adults with recurrent medulloblastoma, six patients were treated with aggressive salvage therapy including high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). At relapse, all patients underwent surgical debulking followed by HDCT/ASCT and then...

journal_title：Bone marrow transplantation

authors： Zia MI,Forsyth P,Chaudhry A,Russell J,Stewart DA

更新日期：2002-11-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) can be used to treat children with refractory acute myeloid leukemia (AML). This retrospective analysis aimed to describe the outcomes and risk factors in such children. Data were collected through the nation-wide registry program in Japan. A total of 417 AML (...

journal_title：Bone marrow transplantation

authors： Okamoto Y,Kudo K,Tabuchi K,Tomizawa D,Taga T,Goto H,Yabe H,Nakazawa Y,Koh K,Ikegame K,Yoshida N,Uchida N,Watanabe K,Koga Y,Inoue M,Kato K,Atsuta Y,Ishida H

更新日期：2019-09-01 00:00:00

abstract：:Children with high risk or relapsed acute lymphoblastic leukaemia (ALL) can benefit from allogeneic haematopoietic stem cell transplantation (SCT). To reduce transplantation-associated complications, the BFM study group, the IBFM study group and the PD-WP-EBMT initiated a prospective cooperative multicentre trail for ...

journal_title：Bone marrow transplantation

authors： Peters C,Schrauder A,Schrappe M,von Stackelberg A,Stary J,Yaniv I,Gadner H,Klingebiel T,BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT.

更新日期：2005-03-01 00:00:00

abstract：:When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early a...

journal_title：Bone marrow transplantation

authors： Johnson BD,Drobyski WR,Truitt RL

更新日期：1993-04-01 00:00:00

abstract：:There have been encouraging reports of the use of recombinant tissue plasminogen activator (tPA) in established veno-occlusive disease (VOD). Haemodialysis has been considered a contraindication to this therapy in view of the potential haemostatic complications. We report a case of a woman who developed moderately sev...

journal_title：Bone marrow transplantation

authors： Simpson DR,Browett PJ,Doak PB,Palmer SJ

更新日期：1994-10-01 00:00:00

abstract：:An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

journal_title：Bone marrow transplantation

authors： Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

更新日期：1998-01-01 00:00:00

abstract：:The homing of hematopoietic precursor cells (HPC) within the bone marrow is most likely to be mediated by specific adhesion via surface receptors to cellular and extracellular matrix (ECM) components and to be regulated by cytokines. We investigated the effects of serum and cytokines on the expression of adhesion mole...

journal_title：Bone marrow transplantation

authors： Koenigsmann MP,Koenigsmann M,Notter M,Neuloh M,Mücke C,Thiel E,Berdel WE

更新日期：1998-12-01 00:00:00

abstract：:Twenty eight Hungarian patients lacking a compatible related donor and their 61 HLA-A,B,DR serologically identical potential unrelated donors (selected from BMDW) were investigated in this study. Out of the 61 donor-recipient pairs only 7 (11,5%) proved to be HLA-identical at DNA level. Thirty one pairs (50,8%) differ...

journal_title：Bone marrow transplantation

authors： Pénzes M,Rajczy K,Gyódi E,Petrányi GG

更新日期：1998-12-01 00:00:00

abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

journal_title：Bone marrow transplantation

authors： Landgren O,Devlin S,Boulad M,Mailankody S

更新日期：2016-12-01 00:00:00

abstract：:Propylene Glycol-Free melphalan HCL for Injection (PGF-Mel) is a new formulation that incorporates Captisol, a specially modified cyclodextrin, to improve melphalan stability. In this phase IIa, open-label, randomized, cross-over design bioequivalence study, the pharmacokinetics of PGF-Mel were compared with the marke...

journal_title：Bone marrow transplantation

authors： Aljitawi OS,Ganguly S,Abhyankar SH,Ferree M,Marks R,Pipkin JD,McGuirk JP

更新日期：2014-08-01 00:00:00

abstract：:HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

journal_title：Bone marrow transplantation

authors： Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

更新日期：2018-09-01 00:00:00

abstract：:Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytara...

journal_title：Bone marrow transplantation

authors： Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

更新日期：1998-08-01 00:00:00

abstract：:Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

journal_title：Bone marrow transplantation

authors： Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

更新日期：2010-08-01 00:00:00

abstract：:The aim of the present study was to assess growth, final height, growth hormone (GH) secretion and growth factors after BMT including TBI in childhood. The median age of the 25 participants was 11.3 years at BMT, and a median of 7.5 years had elapsed since BMT. The median height standard deviation score (SDS) declined...

journal_title：Bone marrow transplantation

authors： Holm K,Nysom K,Rasmussen MH,Hertz H,Jacobsen N,Skakkebaek NE,Krabbe S,Müller J

更新日期：1996-07-01 00:00:00

abstract：:Community-acquired respiratory virus (RV) infections are an important cause of disease in immunocompromised adults with cancer. To investigate the viral etiology, incidence, clinical presentation, and outcome of RV infections in an outpatient cohort of adult bone marrow or peripheral blood stem cell transplant (SCT) r...

journal_title：Bone marrow transplantation

authors： Roghmann M,Ball K,Erdman D,Lovchik J,Anderson LJ,Edelman R

更新日期：2003-12-01 00:00:00

abstract：:The toxicity of the conditioning regimen high-dose busulfan (BU) 16 mg/kg followed by cyclophosphamide (CY) 200 mg/kg has been analysed in 60 adult patients (mean age 36 +/- 9 years) with haematological malignancies, a third of whom had advanced disease, all received the graft from fully HLA-identical siblings. Signif...

journal_title：Bone marrow transplantation

authors： Bandini G,Belardinelli A,Rosti G,Calori E,Motta MR,Rizzi S,Benini C,Tura S

更新日期：1994-05-01 00:00:00

abstract：:Cord blood banks are being developed in the United States and Europe. In The Netherlands, the EuroCord Nederland Foundation (ECN) has been established to coordinate the development of a national cord blood bank for unrelated transplants. The aim of ECN is to collect at least 5000 transplants for patients who lack an H...

journal_title：Bone marrow transplantation

authors： Jacobs HC,Falkenburg JH

更新日期：1998-07-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

journal_title：Bone marrow transplantation

authors： Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

更新日期：2020-05-01 00:00:00

abstract：:An 8-year-old boy received an allogeneic bone marrow transplant (BMT) for relapsed T cell acute lymphoblastic leukaemia. Because he was seropositive for cytomegalovirus (CMV), serial virological specimens were taken throughout the transplant period, and included those obtained by sputum induction. Sixty-one days follo...

journal_title：Bone marrow transplantation

authors： Foot AB,Caul EO,Roome AP,Cornish JM,Catterall JR

更新日期：1990-04-01 00:00:00

abstract：:Hemorrhagic cystitis (HC) is a common and sometimes life-threatening complication of hemopoietic cell transplantation (HCT) occurring in 7-52% of transplant recipients. In this setting it is usually either related to the use of cyclophosphamide or to a viral infection (BK, JC viruses and adenovirus type 11). Treatment...

journal_title：Bone marrow transplantation

authors： Giné E,Rovira M,Real I,Burrel M,Montaña J,Carreras E,Montserrat E

更新日期：2003-05-01 00:00:00

abstract：:This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

journal_title：Bone marrow transplantation

authors： Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

更新日期：1990-05-01 00:00:00

abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

journal_title：Bone marrow transplantation

authors： Thompson JS,Chu Y,Glass JF,Brown SA

更新日期：2010-04-01 00:00:00

abstract：:Thrombotic microangiopathy (TM), manifesting clinically as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, is an uncommon complication after bone marrow transplantation (BMT). A retrospective analysis of potential risk factors for TM following allogeneic BMT was performed. Clinical data were analyzed...

journal_title：Bone marrow transplantation

authors： Paquette RL,Tran L,Landaw EM

更新日期：1998-08-01 00:00:00

abstract：:Information regarding the chimeric status of hematopoietic stem cell transplantation (HSCT) recipients is of great significance when comparing different conditioning and prophylactic therapies. In recent years, short tandem repeats/variable number tandem repeats (STRs/VNTRs) have emerged as the best tool for chimerism...

journal_title：Bone marrow transplantation

authors： Talwar S,Khan F,Nityanand S,Agrawal S

更新日期：2007-05-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally for 7 days, and 15 patien...

journal_title：Bone marrow transplantation

authors： Agha-Hosseini F,Mirzaii-Dizgah I,Ghavamzadeh L,Ghavamzadeh A,Tohidast-Acrad Z

更新日期：2007-04-01 00:00:00